Coronary heart disease Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease

@inproceedings{Jernberg2006CoronaryHD,
  title={Coronary heart disease Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease},
  author={Tomas Jernberg and Christopher D. Payne and Kenneth J. Winters and Christelle Darstein and John T. Brandt and Joseph A. Jakubowski and Hideo Naganuma and Agneta Siegbahn and Lars Wallentin},
  year={2006}
}
Aims This study was designed to compare the degree of inhibition of platelet aggregation (IPA) of prasugrel with that of clopidogrel in stable aspirin-treated patients with coronary artery disease (CAD). Methods and results Subjects (n 1⁄4 101) were randomly assigned to the following loading dose (LD) (day 1)/ maintenance dose (MD) (days 2–28) combinations: prasugrel, 40 mg/5 mg; 40 mg/7.5 mg; 60 mg/10 mg; 60 mg/15 mg; or clopidogrel, 300 mg/75 mg. Turbidometric platelet aggregation was… CONTINUE READING

Figures and Tables from this paper.

Citations

Publications citing this paper.
SHOWING 1-7 OF 7 CITATIONS

Prasugrel, ein neues Thienopyridin

VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 23 REFERENCES

Durability of platelet inhibition by clopidogrel.

  • The American journal of cardiology
  • 2003
VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL

Active metabolites of CS-747 (prasugrel, LY640315) and clopidogrel show similar in vitro P2Y12 receptor blockade but greater in vivo potency of CS-747 (abstract no.: P1109)

A Sugidachi, T Ogawa, +3 authors A Kurihara
  • J Thromb Haemost
  • 2005
VIEW 1 EXCERPT